As global markets navigate a landscape marked by steady inflation and mixed economic signals, Asian equities have shown resilience, with China's recent rally highlighting the region's potential for growth. In this environment, stocks with high insider ownership can be particularly appealing to investors seeking alignment of interests and confidence in management's commitment to long-term success.
Top 10 Growth Companies With High Insider Ownership In Asia
| Name | Insider Ownership | Earnings Growth |
| Zhejiang Leapmotor Technology (SEHK:9863) | 14.6% | 56.0% |
| Suzhou Sunmun Technology (SZSE:300522) | 35.4% | 84.7% |
| Sineng ElectricLtd (SZSE:300827) | 36% | 27.6% |
| Seers Technology (KOSDAQ:A458870) | 34.1% | 84.6% |
| Novoray (SHSE:688300) | 23.6% | 29.8% |
| M31 Technology (TPEX:6643) | 30.7% | 96.8% |
| Laopu Gold (SEHK:6181) | 35.5% | 33.9% |
| Gold Circuit Electronics (TWSE:2368) | 31.4% | 35.2% |
| Fulin Precision (SZSE:300432) | 11.8% | 50.7% |
| Ascentage Pharma Group International (SEHK:6855) | 12.9% | 91.9% |
We're going to check out a few of the best picks from our screener tool.
SK oceanplantLtd (KOSE:A100090)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: SK oceanplant Co.,Ltd. operates in South Korea, focusing on the manufacturing of steel and stainless steel pipes, hull blocks, and shipbuilding equipment, with a market cap of ₩1.37 trillion.
Operations: The company's revenue is primarily derived from its Shipbuilding/Marine segment, which contributes ₩919.68 million, and the Steel Pipe Division, accounting for ₩14.44 million.
Insider Ownership: 20.2%
Earnings Growth Forecast: 47.3% p.a.
SK oceanplant Ltd is experiencing significant earnings growth, forecasted at 47.3% annually over the next three years, outpacing the Korean market's average. Despite a volatile share price recently, revenue is expected to grow at 17.2% annually. Recent M&A activity indicates strategic interest in the company, with The Ocean Consortium proposing to increase its stake. Q2 2025 results showed strong net income growth despite declining sales, highlighting potential operational efficiency improvements or cost management strategies.
- Get an in-depth perspective on SK oceanplantLtd's performance by reading our analyst estimates report here.
- Insights from our recent valuation report point to the potential overvaluation of SK oceanplantLtd shares in the market.
Duality Biotherapeutics (SEHK:9606)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Duality Biotherapeutics, Inc. is a clinical-stage biotech company focused on discovering and developing antibody-drug conjugate therapeutics for cancer and autoimmune diseases, with a market cap of HK$29.84 billion.
Operations: The company's revenue primarily comes from its biotechnology segment, generating CN¥2.17 billion.
Insider Ownership: 13%
Earnings Growth Forecast: 81% p.a.
Duality Biotherapeutics is advancing its pipeline with promising clinical data, particularly for DB-1310, which received FDA Fast Track Designation. The company anticipates strong earnings growth of 80.99% annually and aims to become profitable within three years, surpassing average market growth expectations. Revenue is forecasted to grow at 9.2% per year, slightly above the Hong Kong market rate. Upcoming earnings release on August 26 may provide further insights into financial performance and strategic direction.
- Click here and access our complete growth analysis report to understand the dynamics of Duality Biotherapeutics.
- Our expertly prepared valuation report Duality Biotherapeutics implies its share price may be too high.
Shijiazhuang Shangtai Technology (SZSE:001301)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Shijiazhuang Shangtai Technology Co., Ltd. operates in the technology sector, with a market capitalization of approximately CN¥15.25 billion.
Operations: The company's revenue primarily comes from its Negative Electrode Material segment, generating CN¥5.97 billion, followed by Graphitized Coke at CN¥304.23 million and Diamond Carbon Source at CN¥27.34 million.
Insider Ownership: 39.5%
Earnings Growth Forecast: 21.4% p.a.
Shijiazhuang Shangtai Technology is experiencing robust revenue growth, with recent half-year sales reaching CNY 3.39 billion, up from CNY 2.09 billion a year prior. Despite its earnings forecast of 21.4% per year lagging behind the broader Chinese market, the company trades at a favorable price-to-earnings ratio of 15.9x compared to the market's 43.5x, suggesting good relative value. However, debt coverage by operating cash flow remains an area of concern for financial health evaluation.
- Click to explore a detailed breakdown of our findings in Shijiazhuang Shangtai Technology's earnings growth report.
- In light of our recent valuation report, it seems possible that Shijiazhuang Shangtai Technology is trading behind its estimated value.
Summing It All Up
- Unlock more gems! Our Fast Growing Asian Companies With High Insider Ownership screener has unearthed 603 more companies for you to explore.Click here to unveil our expertly curated list of 606 Fast Growing Asian Companies With High Insider Ownership.
- Ready To Venture Into Other Investment Styles? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if Duality Biotherapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com